AAD 2026Abstract 72744
Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis
A Post-Hoc Analysis of UNCOVER-3
Armstrong A, Merola J, Megna M, Man X, Honma M, Carrascosa JM, Chughtai R, Fotiou K, Sabatino S, NGANTCHA M, Pinter A
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Psoriasis
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.703 · Not in PubMed: details from Crossref